343 related articles for article (PubMed ID: 21058107)
1. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
[TBL] [Abstract][Full Text] [Related]
2. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
Chuang-Stein C; Beltangady M
J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
[TBL] [Abstract][Full Text] [Related]
3. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
Liu Q; Chi GY
J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
[TBL] [Abstract][Full Text] [Related]
4. Comments on the FDA draft guidance on adaptive designs.
Wittes J
J Biopharm Stat; 2010 Nov; 20(6):1166-70. PubMed ID: 21058112
[No Abstract] [Full Text] [Related]
5. Introduction to discussion papers on draft FDA guidance on adaptive designs.
Chang M
J Biopharm Stat; 2010 Nov; 20(6):1113-4. PubMed ID: 21058106
[No Abstract] [Full Text] [Related]
6. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
[TBL] [Abstract][Full Text] [Related]
7. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
Cheng B; Chow SC
J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
[TBL] [Abstract][Full Text] [Related]
8. Review of draft FDA adaptive design guidance.
Cook T; DeMets DL
J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
[TBL] [Abstract][Full Text] [Related]
9. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
10. A note on special articles on adaptive clinical trial designs.
Chow SC
J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
[No Abstract] [Full Text] [Related]
11. Editorial: Adaptive designs: appealing in development of therapeutics, and where do controversies lie?
Wang SJ
J Biopharm Stat; 2010 Nov; 20(6):1083-7. PubMed ID: 21058102
[No Abstract] [Full Text] [Related]
12. Note on special technical issue on adaptive designs for clinical trials.
Liu Q; Chang M
J Biopharm Stat; 2012; 22(4):615-6. PubMed ID: 22651104
[No Abstract] [Full Text] [Related]
13. Innovative approaches for designing and analyzing adaptive dose-ranging trials.
Bornkamp B; Bretz F; Dmitrienko A; Enas G; Gaydos B; Hsu CH; König F; Krams M; Liu Q; Neuenschwander B; Parke T; Pinheiro J; Roy A; Sax R; Shen F
J Biopharm Stat; 2007; 17(6):965-95. PubMed ID: 18027208
[TBL] [Abstract][Full Text] [Related]
14. Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration.
Brannath W; Burger HU; Glimm E; Stallard N; Vandemeulebroecke M; Wassmer G
J Biopharm Stat; 2010 Nov; 20(6):1125-31. PubMed ID: 21058108
[TBL] [Abstract][Full Text] [Related]
15. Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
Grieve AP
J Biopharm Stat; 2007; 17(6):997-1004; discussion 1029-32. PubMed ID: 18027209
[No Abstract] [Full Text] [Related]
16. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
Bottomley A; Jones D; Claassens L
Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
[TBL] [Abstract][Full Text] [Related]
17. Adaptive design in clinical research: issues, opportunities, and recommendations.
Chang M; Chow SC; Pong A
J Biopharm Stat; 2006 May; 16(3):299-309; discussion 311-2. PubMed ID: 16724486
[TBL] [Abstract][Full Text] [Related]
18. Adaptive design clinical trials and trial logistics models in CNS drug development.
Wang SJ; Hung HM; O'Neill R
Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
[TBL] [Abstract][Full Text] [Related]
19. Progress report on the guidance for industry for statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals.
Lin KK
J Biopharm Stat; 2000 Nov; 10(4):481-501. PubMed ID: 11104389
[TBL] [Abstract][Full Text] [Related]
20. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.
Krams M; Burman CF; Dragalin V; Gaydos B; Grieve AP; Pinheiro J; Maurer W; Gallo P
J Biopharm Stat; 2007; 17(6):957-64. PubMed ID: 18027207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
